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cases from 1998/9 to 2001, whilst among all age group, the
incidence dropped from 24.3 to 17.3/100,000 cases. A change
in antibiotic resistance rates, such that macrolide resistance in
invasive pneumococcal disease, fell from 9.3 to 2.9 per 100,000
population in Atlanta, US, has been observed.
Pneumococci are “inhabitants” of the oral ﬂora and colonizes
the nasopharynx, particularly in young children. A recent study
showed that nasopharyngeal carriage has been replaced by the
appearance in frequency of drug-resistant S. pneumoniae (DRSP)
expressing unusual serotypes (6A, 10A, 15A, 15C, 19A, 23A, 33F)
not present in the vaccine, as well as an increase in nontypeable
strains. These nontypeable and “atypical” pneumococci may
become more apparent in the clinical laboratory and be prob-
lematic in identiﬁcation. “Atypical” strains lack one or more of
the deﬁning characteristics of pneumococcus, namely, optochin
(OPT) susceptibility, bile solubility and agglutination with antip-
neumococcal polysaccharide capsule antibodies. Controversial
results also occur from the DNA-based methods for identiﬁcation
of pneumococci. “Atypical” S. pneumoniae has been implicated
in a number of outbreaks of infections in the U.S. and in serious
lower respiratory tract infections, whilst ‘variants’ closely re-
lated to the mitis group have also led to major outbreaks of toxic
shock-like syndrome in China.
A preliminary study indicated 9% of non-typeable S. pneumoniae
from Asian countries were identiﬁed as “atypical” isolates with
incompatible phenotypic and genotypic characteristics, suggest-
ing that this may not be uncommon in Asian countries where
DRSP is prevalent and subjected to intense antibiotic pressure.
S. pneumoniae is undergoing tremendous selective pressure for
capsular switching and interspecies transfer. The introduction of
the protein conjugate vaccine will likely create stronger evo-
lutionary impact to the pneumococcal population, altering its
epidemiology, serotype distribution and prevalence of antibiotic
resistance.
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Pneumococcal disease kills about 2 million every year in the
world today, half of which are children less than 5 years of age
more than 95% are in developing countries of Asia and Africa.
WHO estimates that of those dying from pneumonia, 50% are due
to pneumococcal disease, 20% from H inﬂuenza and the rest from
other bacterial and viral etiologic agents. It is also estimated that
for every 100 pneumonia cases, there will be 10 septicemia and
1 meningitis case as the frequency distribution of invasive pneu-
mococcal disease or IPD. The non-invasive cases are mostly in the
form of otitis media which is considered the most frequent cause
of Out-patient consultation. In both developed and developing
world, otitis media has been a constant cause of hospitalization
and frequent antibiotic therapy with complications of recurrent
otitis media and chronic otitis media that may lead to hearing
loss and learning disabilities.
Streptococcus pneumonia is a highly encapsulated organism,
whose antigenic properties are characterized by more than
90 serotypes, not all of which cause disease but only a few
are highly pathogenic and resistant to antibiotics. Different
geographic locations have been found to have different predomi-
nating serotypes and this has been the basis for surveillance and
continued monitoring of the presently predominating serotypes.
It has also been shown that the incidence of pneumococcal
disease differs from region to region and in different population
and ethnic groups. There has also been reports of the presence
of possible increase in certain serotypes during certain parts of
the year implying the possibility of outbreak characteristics of
this organism and could also be attributed to antibiotic pressure.
In Asia, there is in general a lack of data regarding the inci-
dence and the types of pneumococcal disease predominating
in the countries. It is only recently that Asians are beginning
to become aware of pneumococcal disease with the entry of
information on the impact of pneumococcal conjugate vaccine in
USA and Europe.The lack of awareness on pneumococcal disease
is brought about by non-recognition of the speciﬁc pathogen
due to the difﬁculty of isolating the organism and the limited
resources of blood cultures and other laboratory techniques for
identifying it. Since the invasive form of the disease presents the
same way as other organisms such as H inﬂuenza, Streptococcus
pyogenes, Salmonella, Neisseria meningitides or even some viral
pathogens, the diagnosis of pneumococcal disease has not been
an important part of the medical management among Asian hos-
pitals except for a few industrialized countries.Thus there is very
little awareness of pneumococcal disease in Asia.
With the deaths from Pneumococcal Disease considered by WHO
now as the #1 vaccine-preventable deaths in children today, it is
necessary that countries in Asia begin to acknowledge the valu-
able contribution that pneumococcal conjugate vaccine can do
for the achievement of MDG4 and improvement of child survival.
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Streptococcus pneumoniae is the major cause of life-threatening
invasive diseases, including meningitis, septicaemia and pneumo-
nia. The rapid emergence of multidrug-resistant pneumococcal
strains throughout the world is leading to increased emphasis on
the prevention of pneumococcal infections by vaccination. The
emerging and potential shortcomings of current polysaccharide-
based vaccines prompt researchers to develop a new generation
of pneumococcal vaccines. In the past ﬁve years, we evalu-
ated the protective efﬁcacy of immunizing mice with different
pneumococcal surface protein antigens in invasive-diseasemouse
models, and protection against invasive challenge with 12 dif-
ferent serotypes of S. pneumoniae was assessed in two murine
strains. In addition, we established a functional in vitro assay
to measure the bactericidal activity of antibodies. Our ﬁndings
ﬁrstly demonstrated that active immunization with ClpP and
passive immunization with antibodies speciﬁc for ClpP could
elicit serotype-independent protection against pneumococcal in-
fection, and a mixture of pneumococcal protein antigens (ClpP,
CbpA, and PspA) could further enhance this protection. Anti-
ClpP, anti-CbpA or anti-PspA hyperimmune sera from immunized
mice could signiﬁcantly inhibit the adhesion of Streptococcus
pneumoniae to A549 cells and combination of them resulted in
an additive effect. All antisera could also kill S. pneumoniae
by polymorphonuclear leukocytes in a complement-dependent
way. The anti-infection activity and production of hyperimmune
antibodies induced by immunization with pneumococcal protein
antigens could be abrogated by the depletion of CD4+ T lympho-
cytes. Taken together, our observations provided evidence that
immunization with the mixture of different pneumococcal sur-
face proteins could protect against Streptococcus pneumoniae
more efﬁciently, suggesting that immunization with the combina-
tion of selected pneumococcal virulence proteins is an applicable
way to achieve effective protection against pneumococcal infec-
tion. Our future studies include evaluating protection effects
by the way of combining other promising pneumococcal protein
antigens using different adjuvants in other animal models in
order to ﬁnd out the best formulation of pneumococcal protein
vaccines.
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